Meeting
2021 ASCO Annual Meeting
First-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥ 50%) advanced non-small cell lung cancer (aNSCLC) in the real world: A national French bispective multicentric cohort—ESCKEYP trial (GFPC 05-2018).
Authors
Renaud Descourt
Thoracic Oncology Department, Hospital Morvan, Brest, France
Renaud Descourt , Laurent Greillier , Maurice Perol , Charles Ricordel , Jean-Bernard Auliac , Lionel Falchero , Pierre Demontrond , Remi Veillon , Sabine Vieillot , Florian Guisier , Marie Marcq , Gregoire Justeau , Laurence Bigay Game , Marie Bernardi , Pierre Fournel , Helene Doubre , Julian Pinsolle , Karim Amrane , Christos Chouaid , Chantal Decroisette
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9091)
DOI
10.1200/JCO.2021.39.15_suppl.9091
Abstract #
9091
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Final results from a phase II trial of CIMAvax-EGF and nivolumab as second-line (2L) therapy after platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC).
First Author: Rachel Frascati
Poster
2018 ASCO Annual Meeting
Comparison of outcomes with PD-L1 tumor proportion score (TPS) of 50-74% vs 75-100% in patients with non-small cell lung cancer (NSCLC) treated with first-line PD-1 inhibitors.
First Author: Elizabeth Jimenez Aguilar
First Author: Scott S. Tykodi